Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study to Compare SB16 and Prolia in Postmenopausal Women With Osteoporosis
NCT04664959Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obodence in postmenopausal osteoporosis (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Percent Change From Baseline in Lumbar Spine BMD at Month 12. Started Nov 2020; status: completed.
02
Drugs
obodence
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04664959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664959.